Mesabi Trust (MSB) 10.27 $MSB
Synchrony Financial, Wells Fargo and Navistar slip
AP - Tue Jun 14, 3:18PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
MESO: 3.80 (-0.18), MPAA: 28.68 (-0.82), NAV: 11.73 (-1.41), RVNC: 13.04 (-0.95), WFC: 45.71 (-2.20), SYF: 24.64 (-1.36), MSB: 10.27 (-0.52)
Mesabi Trust Has Returned 103.7% Since SmarTrend Recommendation (MSB)
Comtex SmarTrend(R) - Fri May 13, 12:10AM CDT
SmarTrend identified an Uptrend for Mesabi Trust (NYSE:MSB) on January 29th, 2016 at $4.30. In approximately 3 months, Mesabi Trust has returned 103.72% as of today's recent price of $8.76.
MSB: 10.27 (-0.52)
Mesoblast Reports Financial Results for Period Ended 31 March 2016 and Provides Corporate Update
GlobeNewswire - Mon May 09, 6:04PM CDT
Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today reported its consolidated financial results and operational highlights for the third quarter and nine months ended 31 March 2016.
MESO: 3.80 (-0.18), MSB: 10.27 (-0.52)
Mesoblast to Host Third Quarter and Nine Months Financial Results Conference Call and Webcast
GlobeNewswire - Fri May 06, 7:53AM CDT
Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the third quarter/nine months ended March 31 2016 and provide a corporate update beginning at 7:00 pm Eastern Time on Monday, May 9 2016 and 9:00 am Australian Eastern Standard Time on Tuesday, May 10 2016.
MESO: 3.80 (-0.18), MSB: 10.27 (-0.52)
Uptrend Call Working As Mesabi Trust Stock Rises 99.3% (MSB)
Comtex SmarTrend(R) - Thu May 05, 12:38PM CDT
SmarTrend identified an Uptrend for Mesabi Trust (NYSE:MSB) on January 29th, 2016 at $4.30. In approximately 3 months, Mesabi Trust has returned 99.30% as of today's recent price of $8.57.
MSB: 10.27 (-0.52)
100.2% Return Seen to Date on SmarTrend Mesabi Trust Call (MSB)
Comtex SmarTrend(R) - Wed Apr 20, 12:15AM CDT
SmarTrend identified an Uptrend for Mesabi Trust (NYSE:MSB) on January 29th, 2016 at $4.30. In approximately 3 months, Mesabi Trust has returned 100.23% as of today's recent price of $8.61.
MSB: 10.27 (-0.52)
Mesabi Trust Press Release
BusinessWire - Fri Apr 15, 3:15PM CDT
The Trustees of Mesabi Trust (NYSE:MSB) declared a distribution of twenty cents ($0.20) per Unit of Beneficial Interest payable on May 20, 2016 to Mesabi Trust Unitholders of record at the close of business on April 30, 2016. This compares to no distribution for the same period last year.
MSB: 10.27 (-0.52)
Mesabi Trust Has Returned 33.0% Since SmarTrend Recommendation (MSB)
Comtex SmarTrend(R) - Tue Apr 05, 1:38AM CDT
SmarTrend identified an Uptrend for Mesabi Trust (NYSE:MSB) on January 29th, 2016 at $4.30. In approximately 2 months, Mesabi Trust has returned 33.02% as of today's recent price of $5.72.
MSB: 10.27 (-0.52)
Key United States Patent Granted for Cell-Based Treatment of Rheumatoid Arthritis and Other Rheumatic Conditions
GlobeNewswire - Thu Mar 24, 7:15AM CDT
Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that the United States Patent and Trademark Office has granted a key patent covering the use of the Company's proprietary Mesenchymal Precursor Cells (MPCs) for the treatment or prevention of a broad range of rheumatic conditions, including rheumatoid arthritis.
MESO: 3.80 (-0.18), MSB: 10.27 (-0.52)
Phase 3 Heart Failure Trial Size to be Substantially Reduced Following FDA Discussions
GlobeNewswire - Mon Jan 11, 7:00AM CST
Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that the size of the ongoing Phase 3 trial in chronic heart failure (CHF) of its proprietary cell-based medicine MPC-150-IM is planned to be substantially reduced. This follows communications last month between Mesoblast's development and commercial partner, Teva Pharmaceutical Industries Ltd., and the United States Food and Drug Administration (FDA).
MESO: 3.80 (-0.18), MSB: 10.27 (-0.52)
Mesoblast to Present at the 34th Annual J. P. Morgan Healthcare Conference
GlobeNewswire - Thu Jan 07, 4:56PM CST
Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that it will present at the 34th Annual J. P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 13, 2016, at 3.30 p.m. PST/10.30am Thursday, January 14, 2016 (AEDT).
MESO: 3.80 (-0.18), MSB: 10.27 (-0.52)
Downtrend Call Working As Mesabi Trust Stock Falls 53.6% (MSB)
Comtex SmarTrend(R) - Wed Dec 23, 3:58PM CST
SmarTrend identified a Downtrend for Mesabi Trust (NYSE:MSB) on October 16th, 2015 at $10.98. In approximately 2 months, Mesabi Trust has returned 53.55% as of today's recent price of $5.10.
MSB: 10.27 (-0.52)
BUYINS.NET: SNN, CNQ, MSB, MRLN, MET, SPR Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Thu Dec 17, 5:56AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of San Anton Resource Corp Inc (NYSE:SNN), Canadian Natural Resources Ltd (NYSE:CNQ), Mesabi Trust (NYSE:MSB), Marlin Business Services Corp (NASDAQ:MRLN), Metalore Resources Ltd (NYSE:MET), SPIRIT AEROSYSTEMS HOLDINGS, INC. (NYSE:SPR) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
SNN: 32.62 (-2.03), MRLN: 15.10 (-0.01), MET: 39.44 (-4.73), CNQ: 29.91 (-0.98), SPR: 43.20 (-2.20), MSB: 10.27 (-0.52)
Mesoblast Provides Strategic Update and Reports on First Quarter Financial Results
GlobeNewswire - Wed Dec 16, 3:57PM CST
Materially Strengthened Cash Reserves
MESO: 3.80 (-0.18), MSB: 10.27 (-0.52)
Mesoblast to Host First Quarter Financial Results Conference Call and Webcast on 16 December 2015
GlobeNewswire - Tue Dec 15, 6:51PM CST
Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced it will report financial results for the quarter ended 30 September 2015 after the close of the Nasdaq market on Wednesday 16 December. Mesoblast management will host a conference call to review results and provide a corporate update beginning at 5:00 pm Eastern Time on Wednesday, 16 December / 09:00 am Australian Eastern Daylight Time on Thursday, 17 December.
MESO: 3.80 (-0.18), MSB: 10.27 (-0.52)
Synchrony Financial, Wells Fargo and Navistar slip
AP - Tue Jun 14, 3:18PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
MESO: 3.80 (-0.18), MPAA: 28.68 (-0.82), NAV: 11.73 (-1.41), RVNC: 13.04 (-0.95), WFC: 45.71 (-2.20), SYF: 24.64 (-1.36), MSB: 10.27 (-0.52)
Mesabi Trust Has Returned 103.7% Since SmarTrend Recommendation (MSB)
Comtex SmarTrend(R) - Fri May 13, 12:10AM CDT
SmarTrend identified an Uptrend for Mesabi Trust (NYSE:MSB) on January 29th, 2016 at $4.30. In approximately 3 months, Mesabi Trust has returned 103.72% as of today's recent price of $8.76.
MSB: 10.27 (-0.52)
Mesoblast Reports Financial Results for Period Ended 31 March 2016 and Provides Corporate Update
GlobeNewswire - Mon May 09, 6:04PM CDT
Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today reported its consolidated financial results and operational highlights for the third quarter and nine months ended 31 March 2016.
MESO: 3.80 (-0.18), MSB: 10.27 (-0.52)
Mesoblast to Host Third Quarter and Nine Months Financial Results Conference Call and Webcast
GlobeNewswire - Fri May 06, 7:53AM CDT
Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the third quarter/nine months ended March 31 2016 and provide a corporate update beginning at 7:00 pm Eastern Time on Monday, May 9 2016 and 9:00 am Australian Eastern Standard Time on Tuesday, May 10 2016.
MESO: 3.80 (-0.18), MSB: 10.27 (-0.52)
Uptrend Call Working As Mesabi Trust Stock Rises 99.3% (MSB)
Comtex SmarTrend(R) - Thu May 05, 12:38PM CDT
SmarTrend identified an Uptrend for Mesabi Trust (NYSE:MSB) on January 29th, 2016 at $4.30. In approximately 3 months, Mesabi Trust has returned 99.30% as of today's recent price of $8.57.
MSB: 10.27 (-0.52)
100.2% Return Seen to Date on SmarTrend Mesabi Trust Call (MSB)
Comtex SmarTrend(R) - Wed Apr 20, 12:15AM CDT
SmarTrend identified an Uptrend for Mesabi Trust (NYSE:MSB) on January 29th, 2016 at $4.30. In approximately 3 months, Mesabi Trust has returned 100.23% as of today's recent price of $8.61.
MSB: 10.27 (-0.52)
Mesabi Trust Press Release
BusinessWire - Fri Apr 15, 3:15PM CDT
The Trustees of Mesabi Trust (NYSE:MSB) declared a distribution of twenty cents ($0.20) per Unit of Beneficial Interest payable on May 20, 2016 to Mesabi Trust Unitholders of record at the close of business on April 30, 2016. This compares to no distribution for the same period last year.
MSB: 10.27 (-0.52)
Mesabi Trust Has Returned 33.0% Since SmarTrend Recommendation (MSB)
Comtex SmarTrend(R) - Tue Apr 05, 1:38AM CDT
SmarTrend identified an Uptrend for Mesabi Trust (NYSE:MSB) on January 29th, 2016 at $4.30. In approximately 2 months, Mesabi Trust has returned 33.02% as of today's recent price of $5.72.
MSB: 10.27 (-0.52)
Key United States Patent Granted for Cell-Based Treatment of Rheumatoid Arthritis and Other Rheumatic Conditions
GlobeNewswire - Thu Mar 24, 7:15AM CDT
Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that the United States Patent and Trademark Office has granted a key patent covering the use of the Company's proprietary Mesenchymal Precursor Cells (MPCs) for the treatment or prevention of a broad range of rheumatic conditions, including rheumatoid arthritis.
MESO: 3.80 (-0.18), MSB: 10.27 (-0.52)
Phase 3 Heart Failure Trial Size to be Substantially Reduced Following FDA Discussions
GlobeNewswire - Mon Jan 11, 7:00AM CST
Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that the size of the ongoing Phase 3 trial in chronic heart failure (CHF) of its proprietary cell-based medicine MPC-150-IM is planned to be substantially reduced. This follows communications last month between Mesoblast's development and commercial partner, Teva Pharmaceutical Industries Ltd., and the United States Food and Drug Administration (FDA).
MESO: 3.80 (-0.18), MSB: 10.27 (-0.52)
Mesoblast to Present at the 34th Annual J. P. Morgan Healthcare Conference
GlobeNewswire - Thu Jan 07, 4:56PM CST
Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that it will present at the 34th Annual J. P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 13, 2016, at 3.30 p.m. PST/10.30am Thursday, January 14, 2016 (AEDT).
MESO: 3.80 (-0.18), MSB: 10.27 (-0.52)
Downtrend Call Working As Mesabi Trust Stock Falls 53.6% (MSB)
Comtex SmarTrend(R) - Wed Dec 23, 3:58PM CST
SmarTrend identified a Downtrend for Mesabi Trust (NYSE:MSB) on October 16th, 2015 at $10.98. In approximately 2 months, Mesabi Trust has returned 53.55% as of today's recent price of $5.10.
MSB: 10.27 (-0.52)
BUYINS.NET: SNN, CNQ, MSB, MRLN, MET, SPR Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Thu Dec 17, 5:56AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of San Anton Resource Corp Inc (NYSE:SNN), Canadian Natural Resources Ltd (NYSE:CNQ), Mesabi Trust (NYSE:MSB), Marlin Business Services Corp (NASDAQ:MRLN), Metalore Resources Ltd (NYSE:MET), SPIRIT AEROSYSTEMS HOLDINGS, INC. (NYSE:SPR) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
SNN: 32.62 (-2.03), MRLN: 15.10 (-0.01), MET: 39.44 (-4.73), CNQ: 29.91 (-0.98), SPR: 43.20 (-2.20), MSB: 10.27 (-0.52)
Mesoblast Provides Strategic Update and Reports on First Quarter Financial Results
GlobeNewswire - Wed Dec 16, 3:57PM CST
Materially Strengthened Cash Reserves
MESO: 3.80 (-0.18), MSB: 10.27 (-0.52)
Mesoblast to Host First Quarter Financial Results Conference Call and Webcast on 16 December 2015
GlobeNewswire - Tue Dec 15, 6:51PM CST
Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced it will report financial results for the quarter ended 30 September 2015 after the close of the Nasdaq market on Wednesday 16 December. Mesoblast management will host a conference call to review results and provide a corporate update beginning at 5:00 pm Eastern Time on Wednesday, 16 December / 09:00 am Australian Eastern Daylight Time on Thursday, 17 December.
MESO: 3.80 (-0.18), MSB: 10.27 (-0.52)
